ArkBio Advances Ziresovir into US Phase II Trial for Severe RSV in Infants

Shanghai Ark Biopharmaceutical’s RSV antiviral drug ziresovir received FDA approval to enter a multicenter phase II trial focusing on severely ill infants requiring pediatric intensive care in the US, marking a crucial step towards targeted treatment for a critical unmet medical need.

This Wire brief sits within Fusion42's coverage of Biotech. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.